Captor Therapeutics Spolka Akcyjna (WSE:CTX)
Poland · Delayed Price · Currency is PLN 70.50
-0.20 (-0.28%)
Aug 6, 2026, 9:14 AM CET
WSE:CTX Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.38 | 4.66 | 15.83 | 13.2 | 9.16 | 3.99 | |
Revenue Growth | -82.89% | -70.55% | 19.88% | 44.15% | 129.75% | - |
Cost of Revenue | 0.57 | 1.45 | 5.23 | 6.3 | 2.09 | 0.74 |
Gross Profit | 1.81 | 3.22 | 10.6 | 6.9 | 7.07 | 3.25 |
Selling, General & Admin | 10.17 | 11.14 | 11.46 | 16.14 | 19.56 | 19.55 |
Research & Development | 35.49 | 45.29 | 43.9 | 70.89 | 48.67 | 34.25 |
Other Operating Expenses | -9.56 | -9.65 | -5.79 | -7.11 | -22.79 | -18.84 |
Total Operating Expenses | 36.1 | 46.78 | 49.56 | 79.92 | 45.44 | 34.95 |
Operating Income | -33.82 | -43.56 | -38.97 | -73.02 | -38.36 | -31.71 |
Interest Income | 1.61 | 1.85 | 1.04 | 3.08 | 3.13 | - |
Interest Expense | -0.05 | -0.28 | -0.5 | -0.59 | -0.66 | -0.86 |
Total Non-Operating Income (Expense) | 1.56 | 1.56 | 0.54 | 2.49 | 2.47 | -0.86 |
Pretax Income | -11.35 | -42 | -38.43 | -70.53 | -35.89 | -32.57 |
Provision for Income Taxes | 0.03 | - | - | 0.06 | - | - |
Net Income | -54.13 | -42 | -38.43 | -70.58 | -35.89 | -32.57 |
Net Income to Common | -42.65 | -42 | -38.43 | -70.58 | -35.89 | -32.57 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 6 | 6 | 5 | 5 | 4 | 4 |
Shares Outstanding (Diluted) | 6 | 6 | 5 | 5 | 4 | 4 |
Shares Change | 13.53% | 18.42% | -2.31% | 9.46% | 0.02% | 21.35% |
EPS (Basic) | -7.71 | -7.61 | -8.25 | -15.19 | -8.58 | -7.93 |
EPS (Diluted) | -7.76 | -7.61 | -8.25 | -15.19 | -8.58 | -7.93 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -73.17 | -37.53 | -32.3 | -55.21 | -23.84 | -33.59 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -13.23 | -6.80 | -6.93 | -11.58 | -5.47 | -7.71 |
Gross Margin | 75.99% | 68.99% | 66.95% | 52.28% | 77.21% | 81.41% |
Operating Margin | -1419.82% | -934.78% | -246.24% | -553.11% | -418.91% | -795.51% |
Profit Margin | -2272.46% | -901.22% | -242.82% | -534.69% | -391.94% | -817.16% |
FCF Margin | -3071.66% | -805.36% | -204.12% | -418.22% | -260.32% | -842.60% |
EBITDA | -29.78 | -39.19 | -33.91 | -67.58 | -31.27 | -24.35 |
EBITDA Margin | -1250.17% | -841.05% | -214.27% | -511.90% | -341.45% | -610.99% |
EBIT | -33.82 | -43.56 | -38.97 | -73.02 | -38.36 | -31.71 |
EBIT Margin | -1419.82% | -934.78% | -246.24% | -553.11% | -418.91% | -795.51% |
Effective Tax Rate | -0.24% | 0.00% | 0.00% | -0.08% | 0.00% | 0.00% |